GenMark Diagnostics Enters into License Agreement with PerkinElmer, Inc. for Microfluidics Patent Portfolio

March 29, 2012 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

CARLSBAD, Calif.--(BUSINESS WIRE)--GenMark Diagnostics, Inc. (NASDAQ: GNMK), announced today that it has entered into a license agreement with PerkinElmer, granting GenMark a non-exclusive license under PerkinElmer’s microfluidics patent portfolio.

Twitter
LinkedIn
Facebook
Email
Print

Alliances Regulatory